What is Immunicom?
Immunicom is a pioneering biotechnology firm specializing in innovative immunotherapy solutions. At the heart of its portfolio is the proprietary Immunopheresis technology, a sophisticated therapeutic device designed to enhance patient outcomes by removing systemic barriers that impede the immune system. Unlike traditional pharmacological interventions, this extracorporeal approach aims to mitigate the adverse side effects often associated with cancer treatments.
The company maintains a robust research and development focus, targeting a diverse range of indications including oncology, inflammatory diseases, and renal conditions. By conducting rigorous clinical trials at premier medical institutions, Immunicom is establishing a new paradigm in patient care, prioritizing both efficacy and quality of life. Its market position is defined by its ability to bridge the gap between complex immunological research and practical, device-based therapeutic applications.
How much funding has Immunicom raised?
Immunicom has raised a total of $19.1M across 4 funding rounds:
Series A
$5.5M
Series B
$12.8M
Debt
$350K
Debt
$433K
Series A (2018): $5.5M with participation from Bootstrap Incubation
Series B (2019): $12.9M led by Undisclosed
Debt (2020): $350K supported by PPP
Debt (2021): $433K featuring PPP
Key Investors in Immunicom
Bootstrap Incubation
A venture firm focused on early-stage technology and life sciences, providing foundational support to high-potential startups.
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Immunicom?
With the recent influx of capital, Immunicom is poised to transition into a more aggressive phase of clinical validation and regulatory engagement. The strategic roadmap likely involves scaling the manufacturing of its Immunopheresis devices and expanding the scope of its ongoing clinical trials to include a broader patient demographic. As the company moves toward commercialization, the focus will shift from foundational research to establishing market access and integrating its technology into standard oncology care protocols.
Investors and stakeholders are closely monitoring the company's progress as it navigates the complexities of the biotech regulatory landscape. The successful deployment of these funds will be critical in maintaining the company's competitive edge and achieving its mission of providing transformative, non-pharmacological treatment options for patients facing life-altering diagnoses.
